SlideShare ist ein Scribd-Unternehmen logo
1 von 6
Drug Approval process for US & India
Introduction:
Currently different countries follow different regulation requirements for approval of drug.
For Marketing Authorization Application (MAA) a single regulatory approach a difficult
task. Therefore it is necessary to have knowledge about regulatory requirement for MAA of
each country. The basic regulation can be understood from below figure: 1
Figure 1: The Basic Regulation
Drug approval process in US1-3:
The United States has perhaps the world’s most stringent standards for approval new drugs.
Drug approval standards in the United States are considered by many to be most demanding
in the world.
Investigation New Drug (IND) Application:
Its application filed to FDA in order to start clinical trials in humans if the drug was found to
be safe form the report of Preclinical trials. A firm or institution, called a Sponsor, is
responsible for submitting the IND application. A pre - IND meeting can be arranged with the
FDA to discuss a number of issues:
The design of Animal research.
Protocol for conducting the Clinical trials.
Review the chemistry, manufacturing, and control of the investigational drug.
Such meeting will help the Sponsor to organize animal research, gather data and design the
clinical protocol based on suggestions by FDA. Clear flow chart of the IND process is
illustrated in Figure: 2
Figure 2: Flow chart of Investigation New Drug Application
New Drug Application (NDA):
If clinical studies confirm that a new drug is relatively safe and effective and will not pose
unreasonable risk to patients, the manufacturer files a New Drug Application, the actual
request to manufacture and sell the drug in the United States. The process of NDA has been
illustrated in Figure: 3
Figure 3: Flow chart of New Drug Application.
Abbreviated New Drug Application (ANDA):
It’s an application made for approval of Generic Drugs. The sponsor the not required to
produce the clinical data studies. Instead, that their product is the same as, and bioequivalent
to, a previously approved brand name product. The process of ANDA has been illustrated in
Figure: 4
Figure 4: the flow chart of Abbreviated New Drug Application
Approval of News drug in India4-7:
When a company in India wants to manufacture/import a news drug it has to apply to seek
permission from the licensing authority (DCGI) by filling in Form 44 also submitting the data
as given in Schedule Y of Drugs and Cosmetic Act 1940 and Rules 1945. In order to prove its
efficacy and safety in Indian population it has to conduct clinical trials in accordance with the
guidelines specified in Schedule Y and submit the report of such clinical trials in specified
format.
The process of approval of new drug in India is a very complicated process, which should
meet necessary requirement along with NDA to FDA. The need of the requirements for the
process of approval of new drug in India with emphasis on clinical trials as per Drug Control
department, Government of India.
New Drug Application:
NDA is an application submitted to the FDA for permission to market a new drug. To obtain
this permission a sponsor submits preclinical and clinical studies data to NDA for analyzing
the drug information, description of manufacturing procedures.
After NDA received by the agency, it undergoes a technical screening. This evaluation
ensures that sufficient data and information have been submitted in each area to justify
‘filing’ the application that is FDA formal review. At the conclusion of FDA review of an
NDA, there are 3 possible actions that can be to Sponsor;
Not Approvable – In this latter list of deficiencies and explain the reason.
Approvable – It means that the drug can be approved but minor deficiencies that can be
corrected like-labeling changes and possible request commitment to do post-approval studies.
Approval – It states that the drug is approved.
 If the action taken is either an approvable or a not approvable, then FDA provides
applicant with an opportunity to meet with agency and discuss the deficiencies.
Figure 5: Flow chat of Approval Drug in India
Conclusion:
The Drug approval in US & India are the most demanding in the world. The primary purpose
of the rules governing medicinal product in US & India is to safeguard public health. It is the
role of public regulatory authorities to ensure that pharmaceutical companies comply with
regulations. There are legislations that require drugs to be developed, tested, trialed and
manufactured in according to the guidelines so that they are safe and patient’s well – pending
is protected.
References:
1. Rick NG. Drug from Discovery to approval. 2nd ed. John Wiley & Sons, Inc; 2088.p.
201-202.
2. IPR RB. Robert PM. The Pharmaceutical Regulatory Process. 2nd ed. Informa
healthcare; 2208. P .45.
3. Rick NG. Drugs from Discovery to approval. 2nd ed. John Wiley & Sons, Inc; 2088.p.
203-210.
4. Clinical Trials & Global Clinical Trail (Internet). (cited 2014 January). Available
from: http://edsco.nic.in/clinical_trial.htm.
5. The New Drug Approval Process (Internet). (cited 2014 January). Available from:
http://edsco.nic.in/clinical_trial.htm.
6. CDER Guidance; IND application process (interactive session) (internet). (cited 2014
January). Available from.
http://www.fad.gov/cder/regulatory/applications/ind_page_1.htm.
7. Guidance for industry on preparation of common technical document for
import/manufacture and marketing approval of new drugs for human use. (NEW
DRUG APPLICATION-NDA) (Internet).(cited 2014January) Available from.
http://cdsco.nic.in/CTD_Guidance%20-Final.pdf.

Weitere ähnliche Inhalte

Was ist angesagt?

New Drug Application [NDA]
New Drug Application [NDA]New Drug Application [NDA]
New Drug Application [NDA]Sagar Savale
 
NDA and ANDA regulatory approval process
NDA and ANDA regulatory approval processNDA and ANDA regulatory approval process
NDA and ANDA regulatory approval processNilesh Gawade
 
Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)Swapnil Fernandes
 
central and state Regulatory bodies in India
central and state Regulatory bodies in Indiacentral and state Regulatory bodies in India
central and state Regulatory bodies in Indiasonaliph
 
Approval and Application Process involved in Investigational New Drug (IND)
Approval and Application Process involved in Investigational New Drug (IND)Approval and Application Process involved in Investigational New Drug (IND)
Approval and Application Process involved in Investigational New Drug (IND)Nipun Gupta
 
Clinical research protocols
Clinical research protocolsClinical research protocols
Clinical research protocolsMouryaDeep
 
Generic drugs product development
Generic drugs product developmentGeneric drugs product development
Generic drugs product developmentSachin G
 
Drug regulatory authority
Drug regulatory authority Drug regulatory authority
Drug regulatory authority Rahul Gawande
 
Regulatory affairs overview.pptx
Regulatory affairs overview.pptxRegulatory affairs overview.pptx
Regulatory affairs overview.pptxkajal pradhan
 
IND INDA ANDA Application
IND INDA ANDA ApplicationIND INDA ANDA Application
IND INDA ANDA ApplicationRoshan Bodhe
 

Was ist angesagt? (20)

CTD and eCTD
CTD and eCTDCTD and eCTD
CTD and eCTD
 
New Drug Application [NDA]
New Drug Application [NDA]New Drug Application [NDA]
New Drug Application [NDA]
 
The introduction of an orange book
The introduction of an orange bookThe introduction of an orange book
The introduction of an orange book
 
NDA and ANDA regulatory approval process
NDA and ANDA regulatory approval processNDA and ANDA regulatory approval process
NDA and ANDA regulatory approval process
 
hatch-waxman act@amendments
hatch-waxman act@amendmentshatch-waxman act@amendments
hatch-waxman act@amendments
 
Cdsco ppt
Cdsco pptCdsco ppt
Cdsco ppt
 
Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)
 
central and state Regulatory bodies in India
central and state Regulatory bodies in Indiacentral and state Regulatory bodies in India
central and state Regulatory bodies in India
 
Hatch waxman act
Hatch waxman actHatch waxman act
Hatch waxman act
 
INDA/NDA/ANDA
INDA/NDA/ANDAINDA/NDA/ANDA
INDA/NDA/ANDA
 
Approval and Application Process involved in Investigational New Drug (IND)
Approval and Application Process involved in Investigational New Drug (IND)Approval and Application Process involved in Investigational New Drug (IND)
Approval and Application Process involved in Investigational New Drug (IND)
 
Clinical research protocols
Clinical research protocolsClinical research protocols
Clinical research protocols
 
Generic drugs product development
Generic drugs product developmentGeneric drugs product development
Generic drugs product development
 
New drug approval
New drug approvalNew drug approval
New drug approval
 
ANDA
ANDAANDA
ANDA
 
eCTD
eCTDeCTD
eCTD
 
Drug regulatory authority
Drug regulatory authority Drug regulatory authority
Drug regulatory authority
 
Distribution records
Distribution recordsDistribution records
Distribution records
 
Regulatory affairs overview.pptx
Regulatory affairs overview.pptxRegulatory affairs overview.pptx
Regulatory affairs overview.pptx
 
IND INDA ANDA Application
IND INDA ANDA ApplicationIND INDA ANDA Application
IND INDA ANDA Application
 

Ähnlich wie Drug approval process for US & India

Global Submission Of IND, ANDA & NDA.pptx
Global Submission Of IND, ANDA & NDA.pptxGlobal Submission Of IND, ANDA & NDA.pptx
Global Submission Of IND, ANDA & NDA.pptxPradheepPradheep2
 
Drug approval process
Drug approval processDrug approval process
Drug approval processLitashaGandhi
 
Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe.  Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe. KapilKumar198
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug ApplicationSuhas Reddy C
 
RegulatoryIssues In Drug management cycle
RegulatoryIssues In Drug management cycleRegulatoryIssues In Drug management cycle
RegulatoryIssues In Drug management cycleHarunMohamed7
 
INVESTIGATIONAL NEW DRUG APPLICATION(IND)
INVESTIGATIONAL NEW DRUG APPLICATION(IND) INVESTIGATIONAL NEW DRUG APPLICATION(IND)
INVESTIGATIONAL NEW DRUG APPLICATION(IND) monika maan
 
IND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveIND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveAYESHA NAZEER
 
2.IND AND ANDA.pptx
2.IND AND ANDA.pptx2.IND AND ANDA.pptx
2.IND AND ANDA.pptxbrahmaiahmph
 
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdfGLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdfLokeshThakre6
 
Global Subbmission of IND, NDA, ANDA
Global Subbmission of IND, NDA, ANDA Global Subbmission of IND, NDA, ANDA
Global Subbmission of IND, NDA, ANDA Maruthi.N
 
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...Audumbar Mali
 
New Drug Application In India and US.
New Drug Application In India and US. New Drug Application In India and US.
New Drug Application In India and US. sopansanap1
 
Global Submission of IND& NDA pptx
Global Submission of IND& NDA pptxGlobal Submission of IND& NDA pptx
Global Submission of IND& NDA pptxchitrangpatil700
 
NON CLINICAL ncdd-210117181652.pptx
NON CLINICAL ncdd-210117181652.pptxNON CLINICAL ncdd-210117181652.pptx
NON CLINICAL ncdd-210117181652.pptxDhanaa Dhoni
 
global submission of NDA .pptx
global submission of NDA .pptxglobal submission of NDA .pptx
global submission of NDA .pptxAbdulNaim14
 
NON CLINICAL ncdd-210117181652.pptx
NON CLINICAL ncdd-210117181652.pptxNON CLINICAL ncdd-210117181652.pptx
NON CLINICAL ncdd-210117181652.pptxDhanaa Dhoni
 

Ähnlich wie Drug approval process for US & India (20)

Global Submission Of IND, ANDA & NDA.pptx
Global Submission Of IND, ANDA & NDA.pptxGlobal Submission Of IND, ANDA & NDA.pptx
Global Submission Of IND, ANDA & NDA.pptx
 
Drug approval process
Drug approval processDrug approval process
Drug approval process
 
Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe.  Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe.
 
A REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIA
A REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIAA REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIA
A REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIA
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
 
RegulatoryIssues In Drug management cycle
RegulatoryIssues In Drug management cycleRegulatoryIssues In Drug management cycle
RegulatoryIssues In Drug management cycle
 
INVESTIGATIONAL NEW DRUG APPLICATION(IND)
INVESTIGATIONAL NEW DRUG APPLICATION(IND) INVESTIGATIONAL NEW DRUG APPLICATION(IND)
INVESTIGATIONAL NEW DRUG APPLICATION(IND)
 
Sem 2 nda
Sem 2 ndaSem 2 nda
Sem 2 nda
 
IND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveIND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspective
 
2.IND AND ANDA.pptx
2.IND AND ANDA.pptx2.IND AND ANDA.pptx
2.IND AND ANDA.pptx
 
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdfGLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
 
Overview of FDA requirements for IND
Overview of FDA requirements for INDOverview of FDA requirements for IND
Overview of FDA requirements for IND
 
Global Subbmission of IND, NDA, ANDA
Global Subbmission of IND, NDA, ANDA Global Subbmission of IND, NDA, ANDA
Global Subbmission of IND, NDA, ANDA
 
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
 
New Drug Application In India and US.
New Drug Application In India and US. New Drug Application In India and US.
New Drug Application In India and US.
 
Naresh... anda ppt
Naresh... anda pptNaresh... anda ppt
Naresh... anda ppt
 
Global Submission of IND& NDA pptx
Global Submission of IND& NDA pptxGlobal Submission of IND& NDA pptx
Global Submission of IND& NDA pptx
 
NON CLINICAL ncdd-210117181652.pptx
NON CLINICAL ncdd-210117181652.pptxNON CLINICAL ncdd-210117181652.pptx
NON CLINICAL ncdd-210117181652.pptx
 
global submission of NDA .pptx
global submission of NDA .pptxglobal submission of NDA .pptx
global submission of NDA .pptx
 
NON CLINICAL ncdd-210117181652.pptx
NON CLINICAL ncdd-210117181652.pptxNON CLINICAL ncdd-210117181652.pptx
NON CLINICAL ncdd-210117181652.pptx
 

Kürzlich hochgeladen

CALL ON ➥8923113531 🔝Call Girls Singar Nagar Lucknow best sexual service
CALL ON ➥8923113531 🔝Call Girls Singar Nagar Lucknow best sexual serviceCALL ON ➥8923113531 🔝Call Girls Singar Nagar Lucknow best sexual service
CALL ON ➥8923113531 🔝Call Girls Singar Nagar Lucknow best sexual serviceanilsa9823
 
Indemnity Guarantee Section 124 125 and 126
Indemnity Guarantee Section 124 125 and 126Indemnity Guarantee Section 124 125 and 126
Indemnity Guarantee Section 124 125 and 126Oishi8
 
Mediation ppt for study materials. notes
Mediation ppt for study materials. notesMediation ppt for study materials. notes
Mediation ppt for study materials. notesPRATIKNAYAK31
 
The Active Management Value Ratio: The New Science of Benchmarking Investment...
The Active Management Value Ratio: The New Science of Benchmarking Investment...The Active Management Value Ratio: The New Science of Benchmarking Investment...
The Active Management Value Ratio: The New Science of Benchmarking Investment...James Watkins, III JD CFP®
 
CAFC Chronicles: Costly Tales of Claim Construction Fails
CAFC Chronicles: Costly Tales of Claim Construction FailsCAFC Chronicles: Costly Tales of Claim Construction Fails
CAFC Chronicles: Costly Tales of Claim Construction FailsAurora Consulting
 
Cleades Robinson's Commitment to Service
Cleades Robinson's Commitment to ServiceCleades Robinson's Commitment to Service
Cleades Robinson's Commitment to ServiceCleades Robinson
 
如何办理(MSU文凭证书)密歇根州立大学毕业证学位证书
 如何办理(MSU文凭证书)密歇根州立大学毕业证学位证书 如何办理(MSU文凭证书)密歇根州立大学毕业证学位证书
如何办理(MSU文凭证书)密歇根州立大学毕业证学位证书Sir Lt
 
Legal Risks and Compliance Considerations for Cryptocurrency Exchanges in India
Legal Risks and Compliance Considerations for Cryptocurrency Exchanges in IndiaLegal Risks and Compliance Considerations for Cryptocurrency Exchanges in India
Legal Risks and Compliance Considerations for Cryptocurrency Exchanges in IndiaFinlaw Consultancy Pvt Ltd
 
如何办理(Michigan文凭证书)密歇根大学毕业证学位证书
 如何办理(Michigan文凭证书)密歇根大学毕业证学位证书 如何办理(Michigan文凭证书)密歇根大学毕业证学位证书
如何办理(Michigan文凭证书)密歇根大学毕业证学位证书Sir Lt
 
如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书
如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书
如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书Fir L
 
如何办理提赛德大学毕业证(本硕)Teesside学位证书
如何办理提赛德大学毕业证(本硕)Teesside学位证书如何办理提赛德大学毕业证(本硕)Teesside学位证书
如何办理提赛德大学毕业证(本硕)Teesside学位证书Fir L
 
THE FACTORIES ACT,1948 (2).pptx labour
THE FACTORIES ACT,1948 (2).pptx   labourTHE FACTORIES ACT,1948 (2).pptx   labour
THE FACTORIES ACT,1948 (2).pptx labourBhavikaGholap1
 
Ricky French: Championing Truth and Change in Midlothian
Ricky French: Championing Truth and Change in MidlothianRicky French: Championing Truth and Change in Midlothian
Ricky French: Championing Truth and Change in MidlothianRicky French
 
如何办理澳洲南澳大学(UniSA)毕业证学位证书
如何办理澳洲南澳大学(UniSA)毕业证学位证书如何办理澳洲南澳大学(UniSA)毕业证学位证书
如何办理澳洲南澳大学(UniSA)毕业证学位证书Fir L
 
PPT- Voluntary Liquidation (Under section 59).pptx
PPT- Voluntary Liquidation (Under section 59).pptxPPT- Voluntary Liquidation (Under section 59).pptx
PPT- Voluntary Liquidation (Under section 59).pptxRRR Chambers
 
如何办理伦敦南岸大学毕业证(本硕)LSBU学位证书
如何办理伦敦南岸大学毕业证(本硕)LSBU学位证书如何办理伦敦南岸大学毕业证(本硕)LSBU学位证书
如何办理伦敦南岸大学毕业证(本硕)LSBU学位证书FS LS
 
Chp 1- Contract and its kinds-business law .ppt
Chp 1- Contract and its kinds-business law .pptChp 1- Contract and its kinds-business law .ppt
Chp 1- Contract and its kinds-business law .pptzainabbkhaleeq123
 
Transferable and Non-Transferable Property.pptx
Transferable and Non-Transferable Property.pptxTransferable and Non-Transferable Property.pptx
Transferable and Non-Transferable Property.pptx2020000445musaib
 

Kürzlich hochgeladen (20)

CALL ON ➥8923113531 🔝Call Girls Singar Nagar Lucknow best sexual service
CALL ON ➥8923113531 🔝Call Girls Singar Nagar Lucknow best sexual serviceCALL ON ➥8923113531 🔝Call Girls Singar Nagar Lucknow best sexual service
CALL ON ➥8923113531 🔝Call Girls Singar Nagar Lucknow best sexual service
 
Russian Call Girls Rohini Sector 7 💓 Delhi 9999965857 @Sabina Modi VVIP MODEL...
Russian Call Girls Rohini Sector 7 💓 Delhi 9999965857 @Sabina Modi VVIP MODEL...Russian Call Girls Rohini Sector 7 💓 Delhi 9999965857 @Sabina Modi VVIP MODEL...
Russian Call Girls Rohini Sector 7 💓 Delhi 9999965857 @Sabina Modi VVIP MODEL...
 
Indemnity Guarantee Section 124 125 and 126
Indemnity Guarantee Section 124 125 and 126Indemnity Guarantee Section 124 125 and 126
Indemnity Guarantee Section 124 125 and 126
 
Mediation ppt for study materials. notes
Mediation ppt for study materials. notesMediation ppt for study materials. notes
Mediation ppt for study materials. notes
 
The Active Management Value Ratio: The New Science of Benchmarking Investment...
The Active Management Value Ratio: The New Science of Benchmarking Investment...The Active Management Value Ratio: The New Science of Benchmarking Investment...
The Active Management Value Ratio: The New Science of Benchmarking Investment...
 
CAFC Chronicles: Costly Tales of Claim Construction Fails
CAFC Chronicles: Costly Tales of Claim Construction FailsCAFC Chronicles: Costly Tales of Claim Construction Fails
CAFC Chronicles: Costly Tales of Claim Construction Fails
 
Cleades Robinson's Commitment to Service
Cleades Robinson's Commitment to ServiceCleades Robinson's Commitment to Service
Cleades Robinson's Commitment to Service
 
如何办理(MSU文凭证书)密歇根州立大学毕业证学位证书
 如何办理(MSU文凭证书)密歇根州立大学毕业证学位证书 如何办理(MSU文凭证书)密歇根州立大学毕业证学位证书
如何办理(MSU文凭证书)密歇根州立大学毕业证学位证书
 
Legal Risks and Compliance Considerations for Cryptocurrency Exchanges in India
Legal Risks and Compliance Considerations for Cryptocurrency Exchanges in IndiaLegal Risks and Compliance Considerations for Cryptocurrency Exchanges in India
Legal Risks and Compliance Considerations for Cryptocurrency Exchanges in India
 
如何办理(Michigan文凭证书)密歇根大学毕业证学位证书
 如何办理(Michigan文凭证书)密歇根大学毕业证学位证书 如何办理(Michigan文凭证书)密歇根大学毕业证学位证书
如何办理(Michigan文凭证书)密歇根大学毕业证学位证书
 
如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书
如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书
如何办理美国加州大学欧文分校毕业证(本硕)UCI学位证书
 
Vip Call Girls Greater Noida ➡️ Delhi ➡️ 9999965857 No Advance 24HRS Live
Vip Call Girls Greater Noida ➡️ Delhi ➡️ 9999965857 No Advance 24HRS LiveVip Call Girls Greater Noida ➡️ Delhi ➡️ 9999965857 No Advance 24HRS Live
Vip Call Girls Greater Noida ➡️ Delhi ➡️ 9999965857 No Advance 24HRS Live
 
如何办理提赛德大学毕业证(本硕)Teesside学位证书
如何办理提赛德大学毕业证(本硕)Teesside学位证书如何办理提赛德大学毕业证(本硕)Teesside学位证书
如何办理提赛德大学毕业证(本硕)Teesside学位证书
 
THE FACTORIES ACT,1948 (2).pptx labour
THE FACTORIES ACT,1948 (2).pptx   labourTHE FACTORIES ACT,1948 (2).pptx   labour
THE FACTORIES ACT,1948 (2).pptx labour
 
Ricky French: Championing Truth and Change in Midlothian
Ricky French: Championing Truth and Change in MidlothianRicky French: Championing Truth and Change in Midlothian
Ricky French: Championing Truth and Change in Midlothian
 
如何办理澳洲南澳大学(UniSA)毕业证学位证书
如何办理澳洲南澳大学(UniSA)毕业证学位证书如何办理澳洲南澳大学(UniSA)毕业证学位证书
如何办理澳洲南澳大学(UniSA)毕业证学位证书
 
PPT- Voluntary Liquidation (Under section 59).pptx
PPT- Voluntary Liquidation (Under section 59).pptxPPT- Voluntary Liquidation (Under section 59).pptx
PPT- Voluntary Liquidation (Under section 59).pptx
 
如何办理伦敦南岸大学毕业证(本硕)LSBU学位证书
如何办理伦敦南岸大学毕业证(本硕)LSBU学位证书如何办理伦敦南岸大学毕业证(本硕)LSBU学位证书
如何办理伦敦南岸大学毕业证(本硕)LSBU学位证书
 
Chp 1- Contract and its kinds-business law .ppt
Chp 1- Contract and its kinds-business law .pptChp 1- Contract and its kinds-business law .ppt
Chp 1- Contract and its kinds-business law .ppt
 
Transferable and Non-Transferable Property.pptx
Transferable and Non-Transferable Property.pptxTransferable and Non-Transferable Property.pptx
Transferable and Non-Transferable Property.pptx
 

Drug approval process for US & India

  • 1. Drug Approval process for US & India Introduction: Currently different countries follow different regulation requirements for approval of drug. For Marketing Authorization Application (MAA) a single regulatory approach a difficult task. Therefore it is necessary to have knowledge about regulatory requirement for MAA of each country. The basic regulation can be understood from below figure: 1 Figure 1: The Basic Regulation Drug approval process in US1-3: The United States has perhaps the world’s most stringent standards for approval new drugs. Drug approval standards in the United States are considered by many to be most demanding in the world. Investigation New Drug (IND) Application: Its application filed to FDA in order to start clinical trials in humans if the drug was found to be safe form the report of Preclinical trials. A firm or institution, called a Sponsor, is responsible for submitting the IND application. A pre - IND meeting can be arranged with the FDA to discuss a number of issues: The design of Animal research. Protocol for conducting the Clinical trials. Review the chemistry, manufacturing, and control of the investigational drug. Such meeting will help the Sponsor to organize animal research, gather data and design the clinical protocol based on suggestions by FDA. Clear flow chart of the IND process is illustrated in Figure: 2
  • 2. Figure 2: Flow chart of Investigation New Drug Application New Drug Application (NDA): If clinical studies confirm that a new drug is relatively safe and effective and will not pose unreasonable risk to patients, the manufacturer files a New Drug Application, the actual request to manufacture and sell the drug in the United States. The process of NDA has been illustrated in Figure: 3
  • 3. Figure 3: Flow chart of New Drug Application. Abbreviated New Drug Application (ANDA): It’s an application made for approval of Generic Drugs. The sponsor the not required to produce the clinical data studies. Instead, that their product is the same as, and bioequivalent to, a previously approved brand name product. The process of ANDA has been illustrated in Figure: 4
  • 4. Figure 4: the flow chart of Abbreviated New Drug Application Approval of News drug in India4-7: When a company in India wants to manufacture/import a news drug it has to apply to seek permission from the licensing authority (DCGI) by filling in Form 44 also submitting the data as given in Schedule Y of Drugs and Cosmetic Act 1940 and Rules 1945. In order to prove its efficacy and safety in Indian population it has to conduct clinical trials in accordance with the guidelines specified in Schedule Y and submit the report of such clinical trials in specified format. The process of approval of new drug in India is a very complicated process, which should meet necessary requirement along with NDA to FDA. The need of the requirements for the process of approval of new drug in India with emphasis on clinical trials as per Drug Control department, Government of India.
  • 5. New Drug Application: NDA is an application submitted to the FDA for permission to market a new drug. To obtain this permission a sponsor submits preclinical and clinical studies data to NDA for analyzing the drug information, description of manufacturing procedures. After NDA received by the agency, it undergoes a technical screening. This evaluation ensures that sufficient data and information have been submitted in each area to justify ‘filing’ the application that is FDA formal review. At the conclusion of FDA review of an NDA, there are 3 possible actions that can be to Sponsor; Not Approvable – In this latter list of deficiencies and explain the reason. Approvable – It means that the drug can be approved but minor deficiencies that can be corrected like-labeling changes and possible request commitment to do post-approval studies. Approval – It states that the drug is approved.  If the action taken is either an approvable or a not approvable, then FDA provides applicant with an opportunity to meet with agency and discuss the deficiencies. Figure 5: Flow chat of Approval Drug in India
  • 6. Conclusion: The Drug approval in US & India are the most demanding in the world. The primary purpose of the rules governing medicinal product in US & India is to safeguard public health. It is the role of public regulatory authorities to ensure that pharmaceutical companies comply with regulations. There are legislations that require drugs to be developed, tested, trialed and manufactured in according to the guidelines so that they are safe and patient’s well – pending is protected. References: 1. Rick NG. Drug from Discovery to approval. 2nd ed. John Wiley & Sons, Inc; 2088.p. 201-202. 2. IPR RB. Robert PM. The Pharmaceutical Regulatory Process. 2nd ed. Informa healthcare; 2208. P .45. 3. Rick NG. Drugs from Discovery to approval. 2nd ed. John Wiley & Sons, Inc; 2088.p. 203-210. 4. Clinical Trials & Global Clinical Trail (Internet). (cited 2014 January). Available from: http://edsco.nic.in/clinical_trial.htm. 5. The New Drug Approval Process (Internet). (cited 2014 January). Available from: http://edsco.nic.in/clinical_trial.htm. 6. CDER Guidance; IND application process (interactive session) (internet). (cited 2014 January). Available from. http://www.fad.gov/cder/regulatory/applications/ind_page_1.htm. 7. Guidance for industry on preparation of common technical document for import/manufacture and marketing approval of new drugs for human use. (NEW DRUG APPLICATION-NDA) (Internet).(cited 2014January) Available from. http://cdsco.nic.in/CTD_Guidance%20-Final.pdf.